Abstract | The POLG gene encodes the mitochondrial DNA polymerase that is responsible for replication of the mitochondrial genome. Mutations in POLG can cause early childhood mitochondrial DNA (mtDNA) depletion syndromes or later-onset syndromes arising from mtDNA deletions. POLG mutations are the most common cause of inherited mitochondrial disorders, with as many as 2% of the population carrying these mutations. POLG-related disorders comprise a continuum of overlapping phenotypes with onset from infancy to late adulthood. The six leading disorders caused by POLG mutations are Alpers-Huttenlocher syndrome, which is one of the most severe phenotypes; childhood myocerebrohepatopathy spectrum, which presents within the first 3 years of life; myoclonic epilepsy myopathy sensory ataxia; ataxia neuropathy spectrum; autosomal recessive progressive external ophthalmoplegia; and autosomal dominant progressive external ophthalmoplegia. This Review describes the clinical features, pathophysiology , natural history and treatment of POLG-related disorders, focusing particularly on the neurological manifestations of these conditions.
The development and normal functioning of the CNS depends on a readily available supply of ATP. In neurons, the majority of ATP is generated in the mitochondria by oxidative phosphorylation (OXPHOS) via the electron transport chain (ETC) and ATP synthase. The ETC is composed of complexes I-IV, which set up an electrochemical gradient that drives complex V, the ATP synthase. Of the ~90 proteins that make up the OXPHOS system, 13 are derived from the mitochondrial genome. In humans, the mitochondrial genome is a closed circular DNA molecule of 16,569 bp that also encodes 22 tRNAs and 2 ribosomal RNAs that are required for synthesis of the 13 polypeptides. The mitochondrial DNA (mtDNA) is located in discrete nucleoids localized within the inner matrix of the mitochondrion, each of which contains one or two copies of the mtDNA 1 . The mtDNA is replicated by an assembly of proteins in a replisome consisting of core replication proteins 2 DNA polymerase γ (Pol γ), the mitochondrial single-stranded DNA-binding protein and the Twinkle mtDNA helicase, along with topoisomerases and RNase H activities 3 . Human Pol γ is composed of POLG, a 140 kDa catalytic subunit that is encoded by POLG at chromosomal locus 15q25, and POLG2, a 55 kDa accessory subunit that forms a dimer and is encoded by POLG2 at chromosomal locus 17q24.1 (refs 4-6 ). POLG has DNA polymerase, 3′ to 5′ exonuclease and 5′-deoxyribose phosphate lyase activities 7, 8 . This subunit contains an amino-terminal exonuclease domain connected by a linker region to the carboxy-terminal polymerase domain. POLG2 enhances polymerase processivity by increasing the affinity of the catalytic subunit for DNA [9] [10] [11] . POLG is one of several nuclear genes that are associated with mtDNA depletion or deletion disorders (Table 1) . In 2001, Van Goethem et al. published a seminal paper describing four mutations in POLG that were associated with either autosomal dominant or autosomal recessive progressive external ophthalmoplegia (PEO) 12 .
Between 2003 and 2005, several reports identified POLG mutations in patients with ataxia [13] [14] [15] . Also in this time frame, Alpers-Huttenlocher syndrome (AHS) was found to be caused by recessive mutations in POLG 16, 17 . The high frequency of POLG mutations in the Norwegian and Finnish populations led to calls to include POLG testing as a first-line diagnostic in ataxia syndromes 15, 18 . These reports were the first of many to identify diseaseassociated mutations in the POLG gene. Pathogenic variants in POLG are now known to cause a spectrum of overlapping phenotypes, including some that were clinically defined long before their molecular basis was known. This article reviews these clinical disorders and symptoms associated with POLG-related dis orders, with a focus on the neurological manifestations. The natural history and molecular genetics of POLG-related disorders are also reviewed, along with current treatment options for patients with these conditions.
Epidemiology
Mutations in POLG represent the most prevalent singlegene cause of mitochondrial disease, accounting for 10% of adult mitochondrial disease cases in one large Australian cohort 19 . POLG mutations are the most frequent cause of mitochondrial epilepsy at all ages 20 , and also account for 10-25% of PEO 21 and >10% of ataxia cases 22 . Note that in the text that follows, we refer to these mutations in terms of the resulting amino acid substitution.
Two independent reports identified W748S as a frequent mutation in people with ataxia in the Norwegian population (1 in 100 people in Norway have this mutation in combination with Q497H) 18 and the Finnish population (1 in 125 in the general population) 15 . In an epidemiological study conducted in North East England, clinically manifesting autosomal recessive POLG mutations had a population prevalence of 0.3 per 100,000 adults 23 . As the three most prevalent POLG mutations (A467T, W748S and G848S) have a combined carrier frequency of >1% in northern Europe, application of the Hardy-Weinberg principle suggests that the frequency of recessive POLG disease is likely to be ~1 in 10,000 (ref. 24 ). The discrepancy between this estimate and the figures from North East England could be explained by many affected individuals never being diagnosed or dying in childhood.
Clinical presentations
Age of onset of the POLG-related disorders ranges from infancy to late adulthood. POLG mutations are now known to account for at least six major syndromes. AHS is characterized by childhood-onset progressive and severe encephalopathy with intractable epilepsy and hepatic failure. Individuals with childhood myocerebrohepatopathy spectrum (MCHS) present with developmental delay, lactic acidosis, myopathy and hepatic impairment. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) encompasses a spectrum of disorders with epilepsy, myopathy and ataxia, typically without ophthalmoplegia, including disorders previously described as spinocerebellar ataxia with epilepsy (SCAE); note that long-term survivors of MEMSA can additionally develop PEO. Ataxia neuropathy spectrum (ANS) includes mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). Autosomal recessive PEO (arPEO) is characterized by progressive weakness of the extraocular muscles, resulting in ptosis and ophthalmoparesis without associated systemic involvement. Autosomal dominant PEO (adPEO) typically includes generalized myopathy and variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism and cataracts ( fig. 1 ; Table 2 ).
Most patients with POLG-related disease, particularly those with adolescent-onset or adult-onset disorders, do not present with a discrete clinical syndrome. Therefore, in this Review, instead of describing each of the above syndromic presentations in detail, we will take an ageof-onset and symptom-based approach, which we hope will aid the non-mitochondrial expert in recognizing and diagnosing POLG-related disease.
Early-onset phenotypes
Childhood myocerebrohepatopathy spectrum disorders. Myocerebrohepatopathy is the earliest presentation of biallelic POLG mutations 25 . Affected infants usually present in the first few months of life with severe hypotonia, developmental delay and signs of hepatic impairment such as hypoglycaemia. In one study, median age at onset was 4.7 months (range 0.9-7.0 months) 26 . Other clinical features of MCHS include faltering growth, renal dysfunction and cataracts leading to roving eye movements. Seizures are unusual in this group, perhaps because these infants do not survive long enough to develop seizures; death from liver failure typically occurs before the age of 1 year
.
Alpers-Huttenlocher syndrome. Chronologically, the next presentation of biallelic POLG mutations is AHS, which was initially described as a triad of neurodevelopmental regression, intractable seizures and liver failure 27 . In a multinational cohort, 70% of children with POLG mutations presented with AHS 26 . Disease onset is typically around the end of the first year of life, with focal motor seizures progressing to generalized status epilepticus. Onset of seizures is frequently explosive, and most patients present with refractory convulsive status epilepticus 26, 28 . However, clinical presentation can occur at any time in childhood, and adult onset has even been reported [29] [30] [31] . Preceding development is often normal, but some individuals who present with AHS have a history of prior hypotonia and mild developmental delay. A viral prodrome can sometimes be observed, which might arouse clinical suspicion of encephalitis 32 , and some evidence indicates that an immunological process contributes to the pathology of AHS. For example, some individuals were reported to have oligoclonal bands in their cerebrospinal fluid (CSF) 33 , whereas others had elevated serum levels of antibodies to voltage-gated potassium channels (S.R., unpublished observations). In one case, neuropathology revealed features of acute disseminated encephalomyelitis (ADEM), again suggesting an underlying immune-mediated pathology 33 . The disease course is characterized by recurrent episodes of status epilepticus and epilepsia partialis continua (EPC),
Key points
• POLG encodes the catalytic subunit of DNA polymerase γ, the enzyme responsible for replicating the mitochondrial DNA (mtDNA).
• mutations in POLG are associated with a clinical continuum of heterogeneous syndromes, ranging from infantile-onset epilepsies and liver failure to late-onset ophthalmoplegia and muscle weakness.
• POLG mutations are a frequent cause of mitochondrial disease, particularly mitochondrial epilepsy, polyneuropathy, ataxia and progressive external ophthalmoplegia.
• POLG mutations can lead to depletion of the mtDNA and/or accumulation of multiple mtDNA deletions.
• To a limited extent, clinical phenotypes correlate with the mtDNA phenotype (depletion or deletions).
• No effective disease-modifying therapies are currently available for POLG-related disease, and symptomatic therapies are the mainstay of treatment.
leading to death from refractory status, usually in early to mid childhood 26 . Deficient Pol γ activity in the skeletal muscle and liver of patients with AHS was first reported by Naviaux et al. in 1999 (ref. 34 ), but POLG mutations were not described until 2004 (ref.
16
).
Other epilepsy syndromes
Biallelic POLG mutations are also associated with a number of other epilepsy phenotypes, and are one of the most frequent genetic causes of mitochondrial epilepsy 20, 35, 36 . POLG mutations were the cause of epilepsy in 3 of 42 (7%) of an adult cohort with mitochondrial epilepsy 35 . More than 80% of paediatric patients with POLG mutations have epilepsy at disease onset 26 . A systematic review of 372 patients with POLG-related epilepsy revealed a bimodal age distribution at presentation, with an initial large peak in early childhood and a second peak in adolescence 36 . The median age at onset was 2 years, although POLG-related epilepsy can begin at any age from the first month of life to the seventh decade 36 . Seizure was the initial clinical manifestation in 50% of cases. Seizure semiology was available for 229 patients: 64% had focal motor seizures, 58% had myoclonus, 49% had generalized status epilepticus and 34% had focal motor status. Therefore, we can conclude that status epilepticus is a frequent occurrence in POLGrelated disease. Of 37 patients with POLG-related status epilepticus identified in a systematic review, 13 had status epilepticus alone, 7 had only EPC, and 17 had both generalized status epilepticus and EPC 36 . POLG-related epilepsies can mimic classic mitochondrial syndromes, including myoclonic epilepsy with ragged-red fibres (MERRF) 37 and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) 38 . MEMSA is a form of syndromic POLG-related epilepsy and includes disorders previously referred to as SCAE. In this syndromic presentation, epilepsy is typically associated with myoclonus, myopathy and sensory ataxia. PEO can occur late in the MEMSA disease course.
Progressive external ophthalmoplegia POLG mutations can cause adPEO or arPEO. POLG mutations contributed to ~25% of PEO cases in a London-Oxford cohort 21 and ~10% of cases in a large Italian cohort 39 . PEO was present in 83% of an Italian The table is adapted and updated from ref.
166
. dNTP, deoxynucleotide triphosphate; DOA , autosomal dominant optic atrophy ; IOSCA , infantile-onset spinocerebellar ataxia; MNGIE, mitochondrial neurogastrointestinal encephalopathy ; mtDNA , mitochondrial DNA ; PEO, progressive external ophthalmoplegia; Pol γ, DNA polymerase γ.
www.nature.com/nrneurol cohort of 46 adult patients with POLG mutations and was associated with encephalomyopathy in more than half of these cases 39 . In affected individuals, progressive weakness of the extraocular muscles leads to bilateral, usually symmetrical ptosis and limitation of gaze in all directions. The insidious onset means that diplopia is an uncommon symptom. The muscle weakness can extend to the limb-girdle musculature, manifesting as a proximal myopathy that can progress to a generalized myopathy. Other associated clinical features include ataxia, parkinsonism, depression, sensorineural hearing loss, cataracts and premature ovarian failure 40, 41 .
Ataxia syndromes
Ataxia in POLG-related disease can be sensory or cerebellar. Associated clinical features include dysarthria, encephalopathy with seizures, ophthalmoplegia and peripheral neuropathy. POLG mutations seem to be a fairly frequent cause of cerebellar ataxia, accounting for 9 of 80 cases (11%) in a central European cohort in whom repeat expansion diseases had been excluded 22 . The umbrella term ANS includes disorders previously referred to as MIRAS and SANDO. In one cohort, 6 of 11 patients (55%) with SANDO had POLG mutations leading to multiple mtDNA deletions 42 .
Disorders with prominent neuropathy
In an Italian registry of mitochondrial disease, peripheral neuropathy was a feature in 143 of 1,156 patients (12.4%) 43 . Within the mitochondrial neuropathy cohort, 19 patients (13%) had POLG mutations. Across the entire cohort, 19 of 45 patients (42%) with POLG mutations had neuropathy. In a UK-Australian cohort, 7 of 27 children (26%) with genetically confirmed mitochondrial neuropathy had POLG mutations 44 . POLG mutations are usually associated with an axonal or mixed, predominantly sensory neuropathy, although some patients have a demyelinating neuropathy 43, 44 . More than one-third of the Italian patients with POLG-related neuropathy had neuropathic pain, which is an unusual feature of mitochondrial neuropathy 43 .
MNGIE-like disorder
Five patients with POLG mutations have been reported to have a clinical phenotype closely resembling mitochondrial neurogastrointestinal encephalopathy (MNGIE) syndrome [45] [46] [47] [48] . These patients were aged between 7 and 50 years at the time of disease onset and had prominent symptoms of persistent diarrhoea and cachexia related to gastrointestinal dysmotility, as well as ptosis, proximal myopathy and sensory neuropathy. Patients with classic MNGIE caused by thymidine phosphorylase deficiency have striking white matter changes, but leukoencephalopathy was notably absent in the patients with POLG-related MNGIE reported to date 46 .
Movement disorder syndromes
Parkinsonism is the most frequently observed extrapyramidal movement disorder in patients with POLG mutations and has been associated with both dominant and recessive mutations 40, 41, 49 . In a cohort of adult patients with mitochondrial movement disorders, 5 of 42 (12%) had POLG mutations 50 . These five patients all had parkinsonism, and three also had restless legs syndrome 50 . POLG-related parkinsonism has an earlier onset than idiopathic Parkinson disease -typically ~40 years but as early as the third decade in some families 51 -and is associated with initially asymmetric clinical and imaging features and a good response to levodopa 50 . Palatal tremor also seems to be a characteristic feature in some patients with POLG mutations, occurring together with facial dyskinesia and progressive ataxia in the so-called progressive ataxia palatal tremor (PAPT) syndrome 52, 53 . Dystonia, the most frequent movement disorder in other mitochondrial disorders such as Leigh syndrome, is rarely observed in patients with POLG mutations 54, 55 .
Other phenotypes
The clinical spectrum of POLG-related disease is extremely wide ( fig. 1 ; Table 2 ). Other less frequently reported phenotypes include distal myopathy 56 , premature menopause 40, 41, 57 and cataracts 40, 45, 56 . Neuropsychiatric manifestations, including recurrent major depression, are well known 15 . Prenatal onset of POLG-related disease, characterized by fatal congenital myopathy and gastrointestinal pseudo-obstruction, has also been described 58 .
Environmental triggers and toxins Antiviral drugs that are used to treat HIV infection, such as zidovudine, didanosine, zalcitabine, stavudine, lamivudine, carbovir and tenofovir, have long been known to cause an induced mitochondrial toxicity, leading to peripheral neuropathy and/or myopathy due to inhibition of Pol γ and consequent reduction in mtDNA copy number 59, 60 . In 1990, Dalakas et al. first described a mitochondrial myopathy, characterized by raggedred fibres in muscle and reduced amounts of mtDNA, in patients receiving zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits the HIV life cycle 61, 62 . NRTI-induced mitochondrial dysfunction, also termed mitochondrial toxicity, occurs in as many as 20% of patients undergoing NRTI therapy. This mitochondrial toxicity mimics mitochondrial genetic diseases and induces similar clinical syndromes, including ragged-red muscle fibres, lactic acidosis, myopathies, cardiomyopathies, hepatic steatosis, lipodystrophy and neuropathy 59, 60, 63, 64 . As highlighted below, valproic acid (VPA) is contraindicated in all patients with POLG mutations. VPA can precipitate liver failure in AHS, and sensitivity to this drug has been reported in adolescent and earlyadulthood patients with status epilepticus 65 . VPA is a histone deacetylase inhibitor but is also known to inhibit fatty acid β-oxidation, which primarily occurs in the liver. In contrast to antivirals, VPA further compromises mitochondrial function in POLG-related disease without directly inhibiting Pol γ or acting on the DNA replication pathway.
Patients with POLG-related disorders, similarly to those with other mitochondrial disorders, are hypersensitive to several pharmaceuticals that are known to inhibit mitochondrial function, including antibiotics, statins, anaesthetics and chemotherapeutics 66 . These drugs do not usually cause symptoms in healthy individuals but can aggravate or trigger disease in patients with a genetic ('primary') mitochondrial disorder. Thus, drugs that compromise mitochondrial function should be used with caution in patients with mitochondrial disease, although treating a potentially lifethreatening infection with antibiotics clearly outweighs any theoretical risks of mitochondrial inhibition. Physical stressors such as infection, fever, dehydration and anorexia can result in sudden deterioration in patients with POLG-related disorders and should be avoided if possible.
In the context of mitochondrial toxins, the energetic threshold of mitochondria in different tissues should be taken into account. When ATP production cannot serve the respiratory demands of a certain tissue owing to a decline in mitochondrial function, resulting from a genetic defect and/or environmental exposure, tissue death can ensue. As discussed later in this article, some therapies can upregulate mitochondrial biogenesis and have the potential to overcome mild genetic defects or environmental insults.
Pathophysiology
More than 300 pathogenic mutations of POLG have been reported, as presented in the Human DNA Polymerase Gamma Mutation Database (see Related Links) and in fig. 2 . The consequences of POLG mutations can be divided into two broad groups: multiple mtDNA deletions and mtDNA depletion. No direct genotype-phenotype correlations are evident for POLG mutations: the same mutation can often lead to mtDNA deletions, mtDNA depletion or both, making it difficult to predict the phenotype on the basis of observed mutations. For example, homozygosity for the most common POLG mutation, A467T, has been associated with a range of phenotypes, from childhood-onset fatal AHS to MEMSA, ANS and SANDO 67, 68 . It has been suggested that depletion of mtDNA in neurons is the trigger for development of epilepsy, and preliminary data suggest a relationship between the mtDNA phenotype caused by the POLG mutation and the clinical phenotype. For example, we observed AHS in a child with profound mtDNA depletion, but SANDO in a patient with multiple mtDNA deletions; both individuals had the homozygous A467T POLG genotype 68 . Modelling of mutations on the Pol γ structure has revealed that mutations cluster into five distinct regions [69] [70] [71] . The AHS presentation seems to require a combination of mutations affecting two different conserved regions, whereas ataxia phenotypes were associated with regions affecting the intrinsic processivity domain, possibly modifying the interaction with the accessory subunit encoded by POLG2 (ref.
71
). On the basis of these five distinct clusters, a POLG Pathogenicity Prediction Server was generated to help predict the clinical outcomes of known mutations 72 . However, the onset age and progression of POLG-related disease in patients with the same POLG mutations can span several decades, making predictions difficult. For example, a review of patients with T251I-P587L in trans with G848S showed that the presentation of disease spans >70 years 73 , and another review revealed that disease related to homozygosity for A467T spans at least four decades of life 65, 68 . This enigma of presentation suggests that other factors modify the POLG disease phenotype, including genetic modifiers (nuclear DNA or mtDNA), immune dysfunction, and environmental effects such as viral infection and mitochondrial toxins 74, 75 . In addition to mitochondrial disease, mtDNA mutations have been implicated in the ageing process 76, 77 , and L428P   L424X   Q449X   R722H   H754Q   V855L   S1095R   P1073L   S1080I   R1081Q  A957P  A957V  K1191R  K1191N   R3P   D1184N   S1176L  F1164I   R227W  T251I  G268A   L304R  Q308H  R309L  W312R  G380D   L424X   M603L  G431V  S433C  Y452X  L463F  A467T several lines of evidence suggest that DNA polymerase errors have a prominent role in mtDNA mutation. Mutations in mtDNA can arise through spontaneous errors of DNA replication or through unrepaired damage to mtDNA that introduces miscoding lesions. Owing to its high nucleotide selectivity and exonucleolytic proofreading, POLG exhibits exceptionally high fidelity of DNA replication, with nucleotide misinsertion events occurring only once per 500,000 nucleotides synthesized 78 . The intrinsic 3′ to 5′ exonuclease activity that contributes to replication fidelity can be completely eliminated by substituting alanine for Asp198 and Glu200 in the conserved exonuclease I motif of POLG 79 . Comparison of the in vivo mutational spectrum to the error spectrum generated by human Pol γ in vitro strongly implicated biosynthetic errors by Pol γ as the main driver of point mutations in mtDNA 80 . Furthermore, analysis of agespecific mtDNA sequences revealed mutation signatures more consistent with polymerase errors than with the effects of oxidative damage 81 . Thus, spontaneous replication errors by Pol γ account for the majority of base substitution mutations in mtDNA and are likely to be responsible for the accumulation of point mutations and deletions in mtDNA during ageing 77, [82] [83] [84] . No mouse model of POLG-related disease is available that recapitulates human disease phenotypes. In the absence of such a model, two independent groups created mice with mutations that disrupted the exonuclease function of the mouse POLG protein 85, 86 . Mice that were homozygous for these mutations exhibited premature ageing between 6 and 9 months of age, characterized by greying hair, loss of hair and hearing, curvature of the spine, enlarged hearts, and decreased body weight and bone density 85, 86 . In one of these models, the frequency of mutations was found to be 500-fold higher in heterozygous mice and 2,500-fold higher in homozygous mice than in aged wild-type mice 87 . The heterozygotes were asymptomatic, indicating that a 500-fold increase in mutation frequency was not sufficient to cause phenotypes associated with ageing. Further analysis demonstrated a 90-fold increase in mtDNA deletions in homozygous Polg exonucleasedeficient mice compared with age-matched wild-type or heterozygous mice 88 . Thus, the high frequency of mtDNA deletions in the homozygous mice is thought to be the main driver of the premature ageing phenotype. This mouse model has some relevance to humans in that accumulation of mtDNA deletions seems to be the driving force for mitochondrial dysfunction in adult-onset POLG-related disorders.
Diagnosis
POLG mutations should be considered not only in patients presenting with one of the classic POLG syndromes (MCHS, AHS, MEMSA, ANS and PEO), but also in patients with epilepsy (especially drug-resistant seizures, myoclonus, EPC or convulsive status epilepticus), ataxia, neuropathy, myopathy or other symptoms suggestive of an underlying mitochondrial disorder. Full clinical assessment should encompass a multisystem evaluation, including vision and hearing, and cardiac, hepatic, renal, gastrointestinal and respiratory function.
EEG
In patients presenting with seizures, EEG might provide a diagnostic clue. Children with AHS usually have rhythmic high-amplitude delta with superimposed polyspikes (RHADS) on EEG performed early in the disease course, although later EEG can be nonspecifically abnormal 28 . An occipital lobe predilection for EEG abnormalities is typically observed in POLG-related disease 89 . A systematic review of EEG findings in 72 patients with POLGrelated epilepsy revealed focal changes in most cases. Changes included epileptiform discharges, RHADS and focal slowing, and involved posterior (occipital), frontal or temporal regions (61%, 6% and 2% of cases, respectively) or were multifocal (23% of cases) 36 .
Neuroimaging
A systematic review of neuroimaging findings in 136 pati ents with POLG-related epilepsy revealed that stroke-like lesions were the most prevalent abnormality, being present in 43% of cases 36 . These lesions affected the occipital lobes in half of the cases, but could also involve the parietal, temporal or frontal lobes. Other neuroradiological abnormalities observed in patients with POLG mutations include thalamic (37%), basal ganglia (14%) and cerebellar (17%) lesions, generalized brain atrophy (28%) and involvement of the cerebral white matter (7%) 36 . Importantly, imaging results can be normal in some patients presenting with seizures, so a normal brain MRI scan does not exclude POLGrelated disease. Dopamine transporter imaging demonstrated a bilateral nigrostriatal dopaminergic defect in patients with dominant or recessive POLG mutations 50, 90 . This defect seemed be universal in patients aged >25 years and was not dependent on the presence of clinically overt parkinsonism 91 . Hypertrophic degeneration of the inferior olives seems to be a characteristic feature of the PAPT syndrome 52 .
Biomarkers
No blood or urine biomarkers are known to be specific for POLG-related disease, although peripheral blood levels of lactate can be modestly elevated, and plasma alanine levels might be increased in cases of persistent lactic acidemia. Other metabolites that have been suggested to be biomarkers of mitochondrial disease include fibroblast growth factor 21 (FGF21) 92 and growth and differentiation factor 15 (GDF15) 93 . FGF21, which has been widely reported as a marker for mitochondrial disease manifesting in muscle, is rarely elevated in patients with POLG-related disease, in whom muscle pathology is frequently mild or even absent. Absolute levels of FGF21 have been reported in 17 patients with POLG mutations and ranged from normal (25 pg/ml) to extremely elevated (>4000 pg/ml) 92 . The highest values were seen in patients with AHS and in a patient with MIRAS and terminal status epilepticus. The observation of normal values in several patients with POLG mutations implies that FGF21 is not a useful marker to screen for POLG-related disease, although its levels do seem to correlate with disease severity. Absolute GDF15 values have not been reported in patients with POLG-related disease. Cerebral folate deficiency has been noted in www.nature.com/nrneurol some patients with AHS 94 , and CSF oligoclonal bands have been observed in both children and adults with POLG-related epilepsy, leading to suspicion of ADEM or multiple sclerosis 33, 95 .
Histopathology
In patients with POLG-related disorders, muscle histology might reveal classic mitochondrial features such as ragged-red or cytochrome c oxidase-negative fibres or nonspecific abnormalities such as increased lipid deposition, or can be normal 26 . Some infants with normal muscle biopsies had severely abnormal liver histology 96 . The characteristic liver pathology of AHS, which can be triggered by VPA exposure, includes microvesicular steatosis, bile duct proliferation, hepatocellular necrosis, bridging fibrosis or cirrhosis, and disorganization of the normal architecture 27 . Macroscopic examination of the brain in AHS shows patchy grey matter pathology in the occipital lobes, particularly the striate cortex, and lesions have also been observed in the basal ganglia and thalamus in some cases. Histological features include neuronal depletion, associated with spongiosis and gliosis, progressing through the cortical layers, but affecting the calcarine cortex most severely 27 . ADEM-like neuropathological changes were reported in a 4-year-old boy with recessive POLG mutations 33 . Neuropathological studies in MIRAS revealed subtotal loss of large myelinated fibres in the sural nerve, with severe axonal neuropathy; atrophy of the posterior columns of the spinal cord, posterior spinocerebellar tracts and dentate nuclei; and patchy loss of cerebellar Purkinje cells 97 . Neuronal loss was also observed in the inferior olives, substantia nigra and mediodorsal thalamic nuclei. In addition, the parieto-occipital subcortical white matter showed neuronal loss, gliosis and spongiosis. Distinctive neuropathology was reported in a patient with SANDO, who had multisystem neurodegeneration (pronounced gliosis and neuronal loss) predominantly affecting the brainstem, cerebellum and dentate nuclei, with less severe changes in the basal ganglia and thalamus 98 .
Respiratory chain enzymology
In a subset of individuals with POLG-related disease, respiratory chain enzyme (RCE) assays demonstrate isolated deficiency of complex I or IV or combined deficiencies of multiple enzymes. Interestingly, a review of a multinational cohort revealed normal RCE activities or isolated deficiency of a single enzyme complex (I or IV) in children with AHS but multiple RCE deficiencies in children with MCHS, implying a more severe POLG defect in the latter group 26 . In children with normal muscle RCE activities, RCE deficiencies might be restricted to a clinically affected tissue such as the brain or the liver.
Molecular genetics
If a diagnosis of POLG-related disease is suspected clinically, the most appropriate investigation is direct sequence analysis of the POLG gene. Traditionally, Sanger sequencing has been used, but POLG is increasingly being included in next-generation sequencing (NGS) gene panels (for epilepsy, ataxia or mitochondrial disease, for example), and NGS is likely to be the diagnostic modality of choice going forward. In some regions where the founder mutations A467T, W748S and G848S are particularly prevalent 15, 99 , screening for these common mutations could continue as a first-line investigation. Although hundreds of different diseasecausing POLG mutations have been reported, new potentially pathogenic variants continue to be identified ( fig. 2) . Determining the pathogenicity of these variants of uncertain significance can be challenging, and a Pathogenicity Prediction Server was recently reported 72 .
In some patients with a probable recessive phenotype such as AHS, only one mutation was identified despite an extensive search for a second mutation. Wholegenome DNA and/or RNA sequencing might reveal deep intronic or regulatory sequence variants in such patients in the future 100, 101 . The majority of POLG-related disorders have been associated with one of four common mutations: A467T, W748S, G848S and the T251I-P587L allelic pair (Table 3) . In one study, these mutations accounted for ~50% of all mutations identified in patients with POLG-related disease, and ~75% of patients carried at least one of these four mutations 102 . A467T is considered to be the most common pathogenic variant of POLG (although its prevalence varies by country and population group (Table 3) ), and is estimated to occur in 36% of all alleles associated with POLG-related disease 25, [103] [104] [105] [106] . This mutation is present in 0.2-1.0% of asymptomatic European individuals 12, 18, 105, 107 . The A467T mutation severely reduces Pol γ activity (4% of wild-type activity) by reducing the affinity of the enzyme for deoxynucleotide triphosphates (dNTPs) and lowering catalytic activity 108 . In addition, the POLG subunit containing the A467T variant fails to associate with the POLG2 accessory subunit, which is critical for highly processive DNA synthesis (defined as the number of nucleotides incorporated per DNA-binding event). The combined defects lead to stalling at the replication fork and depletion of mtDNA over time.
The second most common POLG mutation is W748S, which causes a reduction in DNA polymerase activity, low processivity and a severe DNA-binding defect, but normal POLG2 interactions 109 . W748S is NATURe Reviews | NeuROLOGy nearly always found in cis with the E1143G mutation, and is a frequent cause of ANS 15 . The W748S mutant protein has reduced polymerase activity and a decreased affinity for DNA 109 . The E1143G substitution results from a single nucleotide polymorphism that is found in 4% of European populations. The phenotypic effects of W748S are modulated when in cis with E1143G, which is considered a benign variant 109 . The G848S variant is the third most common mutation in the POLG mutation database. This pathogenic variant results in <1% of normal polymerase activity and a defect in DNA-binding function 110 . Gly848 is located in the thumb subdomain of the polymerase active site in a cluster of mutations associated with AHS 110 . An in vitro study showed that mutations in the most conserved sites in this cluster, including G848S, T851A, R852C and R853Q, decreased the activity of Pol γ to <1% of the wild-type level 110 . The T251I and P587L amino acid substitutions, which are usually found in cis and occur in up to 1% of the Italian population, have been implicated in PEO 103 . Individually, these mutations cause a ~30% reduction in DNA polymerase activity, and together they act synergistically to functionally impair polymerase function to levels ~5% of normal owing to a combination of loss of enzyme stability, decreased DNA-binding affinity and reduced catalytic efficiency 111 . The Y955C variant is the most common autosomal dominant mutation in POLG and causes PEO. The symptoms can progress to include parkinsonism or premature ovarian failure 40, 41 . The alteration to cysteine at position 955 of POLG causes a severe reduction in Pol γ activity (<1% of wild-type) 112, 113 .
Differential diagnosis
In addition to POLG, mutations in many genes encoding proteins that regulate mtRNA stability have been shown to cause conditions resembling POLG-related disease (Table 1) ).
The differential diagnosis of treatment-resistant convulsive status epilepticus in childhood includes febrile infection-related epilepsy syndrome, for which a genetic basis has not yet been established 115 . Other causes of acute liver failure in infancy include mtDNA depletion due to DGUOK and MPV17 mutations, and impaired mitochondrial translation caused by TRMU mutations 96, 116 . However, the differential diagnosis is wide and includes other inborn errors of metabolism, for example, recurrent acute liver failure caused by biallelic mutations in the NBAS gene 117 , and viral infections. Liver failure of later onset might be attributable to drug toxicity.
Natural history
The epileptic phenotypes of POLG-related disease are associated with high morbidity and mortality, especially AHS, which is usually characterized by relentless disease progression leading to death from status epilepticus in early childhood 26 . One study of POLG-related epilepsy suggested that homozygous mutations in the linker region of the enzyme were associated with later onset and longer survival compared with compound heterozygous mutations affecting the same domain 36, 65 . Another study suggested that the presence of anaemia correlates with worse outcomes in POLG-related disease 45 . Liver failure in POLG-related disorders is usually fatal, although one report describes a patient who recovered spontaneously from acute liver failure and remained well 6 years later 96 .
Treatment
Evidence-based therapies for POLG-related disorders are currently lacking. No randomized controlled clinical trials have been performed for these conditions, and symptomatic therapies are the mainstay of treatment.
Management of epilepsy
No antiepileptic drug (AED) has been shown to be particularly efficacious for POLG-related seizures, which are frequently resistant to multiple AEDs. A systematic review revealed that the mean number of AEDs used in POLG-related epilepsy was three, and some patients received as many as ten drugs 36 . The best options for POLG-related epilepsy seem to be a sodium channel blocker (for example, lamotrigine) together with a benzodiazepine (for example, clobazam) and levetiracetam or topiramate as needed 89, 118 . However, randomized clinical trials of AEDs have not been performed in POLGrelated disease, and trial design is likely to be extremely challenging in view of the clinical heterogeneity of affected patients and unpredictable disease course.
VPA is absolutely contraindicated in patients with POLG-related disease as it can precipitate liver failure (although some patients might develop liver failure without prior VPA exposure, and VPA hepatotoxicity is occasionally reversible 119 ). It is recommended that the POLG gene should be sequenced before prescribing VPA to patients with status epilepticus 120 . Management of status epilepticus is particularly challenging in patients with POLG mutations. Many therapeutic modalities have been tried, including anaesthetic agents such as ketamine 121 , magnesium infusion 122 , highdose steroids and intravenous immunoglobulin 123 , and even palliative functional hemispherectomy in one individual with AHS 124 , but an effective therapeutic regimen remains elusive.
Other supportive therapies
Other important symptomatic therapies for patients with POLG-related disease include removal of cataracts where necessary, brow suspension surgery for PEO, levodopa for individuals with symptoms of parkinsonism, www.nature.com/nrneurol antidepressants, and psychological support for affected patients and their carers. Mitochondrial 'cocktails' of various combinations of vitamin supplements and/or antioxidants are frequently prescribed for patients with POLG mutations in an attempt to support mitochondrial function, but no evidence-based rationale exists for their use 125 .
Liver transplantation
Since 1992, orthotopic liver transplantation has been reported in >40 individuals with presumed or genetically confirmed POLG-related disease, including pati ents with VPA-associated acute liver failure (VPA-ALF), and has shown life-saving potential for adolescents and adults 25, 126, 127 (Table 4 ). However, in younger patients, death from progressive neurological decline has frequently occurred within 1 year of the transplant 116, 128, 129 . This experience has led to the suggestion that VPA-ALF is an absolute contraindication to liver transplantation in children aged <10 years, in whom neurological progression post-transplant seems almost inevitable, but that transplantation might be considered in carefully screened teenagers or adults 129 . In patients who are not considered suitable for liver transplantation, supportive therapy including carnitine should continue, as spontaneous resolution of VPA-ALF has occasionally been reported in patients with confirmed POLG mutations 119, 130 .
Experimental approaches
The ketogenic diet -a high-fat, low-carbohydrate diet -has been proposed as a therapy for various mitochondrial diseases on the basis of observations in cell and animal models 131, 132 . Treatment with a ketogenic or lowglycaemic-index diet has been reported in only a handful of patients with POLG mutations 49, 133, 134 , without clear evidence of efficacy.
Decanoic acid, a fatty acid that is elevated in the blood of individuals on a ketogenic diet, has been implicated as an effective anticonvulsant agent. This compound seems to have pleiotropic roles, including stimulation of mitochondrial biogenesis and inhibition of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors 135, 136 . Preliminary preclinical data in complex Ideficient patient fibroblasts were promising 137 , but cells with POLG mutations have not yet been studied.
A high-throughput drug screen in Saccharomyces cerevisiae identified clofilium tosylate, a potassium channel blocker that functions as an anti-arrhythmic agent, 171 6 POLG-related disease Not specified Direct worsening of mitochondrial disease symptoms post-transplant in three patients, with two dying shortly after transplantation; two patients with POLG-related AHS had no complications or symptom progression (ages not given)
AHS, Alpers-Huttenlocher syndrome (clinical and/or neuropathological diagnosis); VPA-ALF, valproic acid-associated acute liver failure.
NATURe Reviews | NeuROLOGy as a potential mtDNA stabilizer in POLG deficiency, although the precise mechanism of action was unclear 138 . Further studies in a Caenorhabditis elegans model and fibroblasts from a single POLG-deficient patient with MCHS showed promise 138 . However, additional work is needed to assess the clinical applicability of clofilium tosylate and related compounds.
Nucleotides and nucleosides have been suggested as potential therapies for mtDNA depletion disorders arising from deficient intramitochondrial nucleoside salvage 139, 140 . However, as might be expected given that impaired nucleoside supply is not thought to be the primary disease mechanism in POLG-related disorders, nucleotide supplementation did not correct mtDNA depletion in POLG-deficient patient fibroblasts 141 . Gene therapy has been reported to be successful in animal models of other mitochondrial disorders, including MNGIE and ethylmalonic encephalopathy 142, 143 , and might be a future therapeutic approach for POLG-related disease.
Conclusions
Mutations in POLG, which encodes the catalytic subunit of Pol γ, are associated with numerous clinically heterogeneous syndromes characterized by a quantitative and/or qualitative mtDNA defect. Seizures dominate the clinical picture, not only in childhood-onset cases, but also in POLG-related disease presenting in early adult life and in the adult ataxic forms of the disease, indicating a poor prognosis. Other disease manifestations include ataxia, movement disorders, PEO, myopathy and peripheral neuropathy, as well as multisystem features such as cataracts, cardiomyopathy, premature menopause and gastrointestinal pseudo-obstruction. Despite tremendous advances in mitochondrial disease diagnostics in recent years, effective disease-modifying therapies are still lacking, although some promising candidates are beginning to emerge.
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